<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048381</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01810; bb21Eckstein2</org_study_id>
    <nct_id>NCT05048381</nct_id>
  </id_info>
  <brief_title>miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)</brief_title>
  <official_title>miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fachhochschule Nordwestschweiz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The detection of miRNA (non-coding ribonucleic acid) in the blood in the context of active&#xD;
      tuberculosis is an innovative approach to the detection of new disease-specific biomarkers.&#xD;
&#xD;
      The primary goal of this analysis is to define, for the first time, an miRNA fingerprint for&#xD;
      tuberculosis in sweat. Samples that were collected as part of the Sweatb Study (NCT03667742)&#xD;
      project are examined for the occurrence of disease-specific, non-coding miRNAs to define new&#xD;
      biomarkers in the sweat. These biomarkers can be detected non-invasively and will help in the&#xD;
      detection of patients with active tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of miRNA (non-coding ribonucleic acid) in sweat</measure>
    <time_frame>Sweat samples taken at baseline</time_frame>
    <description>Analysis of sweat protein markers in patients with active tuberculosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of miRNA (non-coding ribonucleic acid) in blood</measure>
    <time_frame>Blood samples taken at baseline</time_frame>
    <description>Analysis of blood protein markers in patients with active tuberculosis</description>
  </primary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Active Tuberculosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Next Generation Sequencing</intervention_name>
    <description>Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All participants in the Sweatb study (NCT03667742)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients&#xD;
&#xD;
          -  Ability to understand the purpose of the study, provide signed and dated informed&#xD;
             consent by patient or his/her legal representative&#xD;
&#xD;
          -  In-patients with acute tuberculosis, suspected tuberculosis or other pulmonary&#xD;
             diseases (pneumonia, Bronchitis, COPD)&#xD;
&#xD;
        Inclusion criteria Healthy Donors:&#xD;
&#xD;
          -  negative for Quantiferon- TB Gold Plus Test or ELISpot&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Written rejection of the consent for the further use of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Eckstein, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Medical Information Office (CMIO), University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Eckstein, Prof. Dr. med.</last_name>
    <phone>+41 6132876 89</phone>
    <email>jens.eckstein@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noé Brasier, Dr. med.</last_name>
    <phone>+41 61 265 25 25</phone>
    <email>NoeKarl.Brasier@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chief Medical Information Office (CMIO), University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Eckstein, Prof. Dr. med.</last_name>
      <phone>+41 6132876 89</phone>
      <email>jens.eckstein@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Noé Brasier, Dr. med.</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>NoeKarl.Brasier@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jens Eckstein, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noé Brasier, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>miRNA</keyword>
  <keyword>Mycobacterium Tuberculosis</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

